Table 2.

Main clinical and MRI outcome parameters after 12 months.

	Verum	Placebo
Patients with relapses (n)	2	6	n.s.a
Mean EDSS change [SE]	−0.25 [0.14]	+ 0.38 [0.25]	n.s.b
Mean PASAT change [SE]	+3.2 [2.0]	+10.7 [3.2]	n.s.b
Mean TWT z-score change [SE]	+0.8 [0.1]	+0.2 [0.16]	n.s.b
Mean 9HPT z-score change [SE]	+0.5 [0.2]	+0.1 [0.16]	n.s.b
Total patients with CEL (n)	1	5	n.s.a
Total number of new T2w lesions (n)	+6	+7	n.s.b
Mean T2w volume change (mm3)	+306	+828	n.s.b

This table displays the most relevant outcome parameters after 12 months of double blind treatment. There were no significant differences between verum and placebo groups. EDSS, expanded disability status scale; CEL, contrast enhancing lesions; n, number; n.s, not significant; PASAT, paced auditory serial addition test; TWT, timed walk test; SE, standard error; 9HPT, 9-hole peg test.

^aExact Chi-Square tests.

^bExact Mann Whitney U-tests.